In agreement with our work, previous studies have reported reduced reactivity of myelin-specific CD4+ T-cells ex vivo in IFN-β treated MS [26,27]; these studies used an assay similar to our own with PBMCs cultured in AB-serum-supplemented media. This evidence concerns the gene IFNB1 and myeloid sarcoma.